Lisa Rojkjaer
Directeur Technique/Scientifique/R&D chez RIGEL PHARMACEUTICALS, INC.
Postes actifs de Lisa Rojkjaer
Sociétés | Poste | Début | Fin |
---|---|---|---|
RIGEL PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 12/03/2024 | - |
Historique de carrière de Lisa Rojkjaer
Anciens postes connus de Lisa Rojkjaer
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIRACTA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2020 | 05/05/2023 |
THOR MEDICAL | Directeur Technique/Scientifique/R&D | 15/11/2016 | 01/04/2020 |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/10/2013 | 01/11/2016 |
SANGAMO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 16/05/2023 | - |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Directeur Technique/Scientifique/R&D | 01/05/2020 | - |
VIRACTA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 24/02/2021 | - |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - | - |
MORPHOSYS AG | Corporate Officer/Principal | - | - |
░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Lisa Rojkjaer
University of Toronto | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Suisse | 3 |
Canada | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 7 |
Corporate Officer/Principal | 4 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 12 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
MOLECULAR PARTNERS AG | Health Technology |
MORPHOSYS AG | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
SANGAMO THERAPEUTICS, INC. | Health Technology |
RIGEL PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Nordic Nanovector ASA
Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
- Bourse
- Insiders
- Lisa Rojkjaer
- Expérience